Vertex Pharma (VRTX) Tops Q1 EPS by 14c, Misses on Revenue; Offers FY26 Revenue Guidance

Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $4.47, $0.14 better than the analyst estimate of $4.33. Revenue for the quarter came in at $2.99 billion versus the consensus estimate of $3.03 billion.

GUIDANCE:

Vertex Pharma sees FY2026 revenue of $12.95-13.1 billion, versus the consensus of $13.05 billion.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.

You May Also Be Interested In

• U.S. and Denmark close in on a Greenland deal - Reuters
• Empire Petroleum (EP) files $150M mixed shelf
• RBC Capital Reiterates Sector Perform Rating on Freehold Royalties Ltd. (FRU:CN) (FRHLF)